Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
53
resultados
Última actualización
02/11/2026 [06:45:00]
Resumen de: WO2026226955A1
The invention provides novel compounds of Formulas (I)-(III), as described herein. Also provided are compositions of these compounds, methods of making the compounds, and methods 5 of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C and cancers such as leukemia.
Resumen de: US20260335342A1
A method for treating lymphoma is provided. A pharmaceutical composition for treatment of lymphoma, including BCV, a pharmaceutically acceptable salt thereof, or a solvate thereof is used. The lymphoma may be EBV-positive lymphoma. The lymphoma may be MYC-positive lymphoma. The pharmaceutical composition may be used in combination with a chemotherapeutic agent.
Resumen de: US20260337562A1
Hematopoietic stem progenitor cells (HSPCs) are multipotent, self-renewing, progenitor cells capable of generating every type of blood cell arising from both the lymphoid and myeloid lineages. Since many types of cancer, including leukemia, lymphoma, and myeloma, affect the development, function, and viability of a number of blood cells, finding a means of producing HSPCs has become an important area of research. Disclosed are CD34+hematopoietic stem progenitor cells (HSPCs) generated from induced pluripotent stem cells (IPSCs) and T cells generated from IPSCs under minimal cytokine conditions, and methods of generating and using the same for the treatment of diseases and disorders.
Resumen de: AU2025266243A1
Disclosed herein is a platform technology for designing T cell engagers. Examples of such T cell engagers and nucleic acids (e.g., mRNAs) encoding same as well as lipid nanoparticles comprising nucleic acids (e.g., mRNAs) encoding the T cell engagers are provided. Such T cell engagers can be used to treat cancers such as FCRH5+, GPRC5D+, and/or BCMA+ cancers, including hematological malignancies such as multiple myeloma (e.g., advanced MM, RRMM), B cell lymphoma, and myeloid cancers.
Resumen de: WO2026227004A1
The present invention is directed to substituted indolenine inhibitors of PIM1 kinase, pharmaceutical compositions comprising them, and their use in the treatment of PIMl-overexpressing diseases including breast, prostate, lung, gastric, colorectal, pancreatic, renal, testicular, and head and neck cancers, as well as lymphomas, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myeloid leukemia (CML).
Resumen de: US20260338776A1
In one embodiment, a reagent kit for analysis of blood cells by a spectral flow cytometer having at least three lasers and at least thirty-eight detectors is disclosed. The reagent kit includes a plurality of vials with a plurality of fluorochromes respectively conjugated to a plurality of antibody clones for markers of cells in peripheral blood mononuclear cells (PBMC) and whole blood to analyze and identify healthy cells from leukemia cells in a biological sample in a single sample test tube. The pairing of reagents and fluorochromes in the reagent kit are identified in a simplified format by a flow cytometer panel for use with the spectral flow cytometer.
Resumen de: WO2025134050A1
Embodiments of the present disclosure relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the multiple myeloma.
Resumen de: EP4831179A1
The invention provides 4,6-disubstituted-7H-pyrrolo2,3-dpyrimidines of general formula I,wherein all the variables are defined in the claims. The compounds of this invention are potent and selective inhibitors of CDK9 and are useful in the treatment of leukemias, solid tumors, lymphomas, neutrophilic dermatoses or netrophilic diseases.
Resumen de: US20260325562A1
Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.
Resumen de: AU2025269945A1
Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.
Resumen de: WO2026221060A1
The present invention addresses the problem of providing a biomarker for predicting the prognosis of IDD-LPD. The prognosis of IDD-LPD is predicted by using the presence or absence of deletion of a specific region in a human chromosome or the presence or absence of a mutation in a specific human gene region as an indicator.
Resumen de: US20260327304A1
The present disclosure provides an antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. The present disclosure also relates to a method for treating a solid tumor, multiple myeloma, or leukemia such as acute myeloid leukemia (AML) using the anti-LILRB4×CD3 bispecific antibody of the present disclosure.
Resumen de: WO2026220363A2
Provided herein are methods of treating multiple myeloma, such as relapsed and/or refractory multiple myeloma. The methods involve administering to human patients diagnosed with multiple myeloma an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate), bortezomib, and dexamethasone; or an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate), pomalidomide, and dexamethasone. The disclosure further relates to dosing regimen modifications for the disclosed anti-BCMA antigen binding proteins in response to ocular adverse events in a subject being treated with the anti-BCMA antigen binding protein.
Resumen de: WO2026219079A1
Disclosed is use of a combination of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) and an erythroid maturation agent in rare anemias. In particular, a combination of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) and erythroid maturation agents has a synergistic effect in the treatment of rare anemias such as sickle cell disease (sickle cell anemia, SCD), β-thalassemia (β-thal), and myelodysplastic syndrome anemia (MDS anemia).
Resumen de: US20260327717A1
The invention features methods for the identification of genomic aberrations in circulating tumor cells isolated from peripheral blood. In embodiments, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
Resumen de: WO2026222428A1
The present disclosure provides CLL-1/CD33 dual-targeting chimeric antigen receptors (CARs). The CARs may comprise a VHH targeting CLL-1 and a VHH targeting CD33. The chimeric antigen receptors can be used to treat cancer, such as acute myeloid leukemia (AML).
Resumen de: US20260327331A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: US20260325545A1
0000 Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
0000
Resumen de: US20260327334A1
The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMOD and a steroid. Such combinations may be used for the treatment of multiple myeloma.
Resumen de: US20260325633A1
At this invention I presents medication to leukemia and cancer/tumors.
Resumen de: WO2026221354A1
The present invention relates to a pharmaceutical composition for preventing or treating Bcl-2 family inhibitor-resistant acute myeloid leukemia. More specifically, the present invention may provide a pharmaceutical composition for preventing or treating cancer that has acquired resistance to a Bcl-2 family inhibitor, which is used as a conventional therapeutic agent for resistant acute myeloid leukemia, through inhibition of the expression of nucleolin and Mcl-1.
Resumen de: WO2025128434A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Resumen de: WO2026217529A1
The disclosure herein provides compositions for the treatment of cancer. In some embodiments, the method of treating cancer comprising: administering to a subject in need thereof celastrol and one or more additional agents selected from: simvastatin; fluoxetine; memantine; auranofin; colchicine; adefovir; pyrvinium; digoxin; fluvastatin; doxepin; and gemcitabine. In some embodiments, the disclosure provides compositions for the treatment of lung cancer, breast cancer, colorectal cancer, skin cancer, brain cancer, leukemia, pancreatic cancer, esophageal cancer, cervical cancer, head and neck cancer, or ovarian cancer.
Resumen de: US20260315486A1
0000 The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Nº publicación: US20260317835A1 15/10/2026
Solicitante:
DANA FARBER CANCER INST INC [US]
THE GENERAL HOSPITAL CORP [US]
DANA-FARBER CANCER INSTITUTE, INC.
THE GENERAL HOSPITAL CORPORATION
Resumen de: US20260317835A1
0000 There are provided methods for detecting and classifying a B-cell malignancy selected from the group consisting of a B-cell lymphoma, a B-cell leukemia, and a plasma cell dyscrasia in a subject. The methods employ a tumor cell profiling algorithm to analyze single-cell RNA sequencing data obtained from a sample of, e.g., the subject's blood or bone marrow, enriched for a cell type comprising tumoral cells using a cell surface marker. This algorithm identifies one or more one or more expanded clonal cell populations and categorizes each of the one or more expanded clonal cell populations as malignant or pre-malignant tumor cell population if expression of one or more malignancy markers is detected. The one or more malignant or pre-malignant tumor cell population(s) can be analyzed using a statistical model or machine learning algorithm to classify the B-cell malignancy.
BOPI
Sede Electrónica
